Schechter Investment Advisors’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Schechter Investment Advisors’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,087	Closed	-$861	–	765
2023 Q1	$861	Hold	26,087	–	–	﹤0.01%	695
2022 Q4	$1.45K	Buy	+26,087	New	+$929	﹤0.01%	845

Schechter Investment Advisors's EUCRW Position: Q2 2023 in Review

Schechter Investment Advisors sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 26,087 shares — an estimated $861 sold.

Schechter Investment Advisors first reported a position in EUCRW in Q4 2022 and held it in 2 quarters. The position peaked at $1.45K in Q4 2022. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Schechter Investment Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Schechter Investment Advisors sold 26,087 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $861.
Schechter Investment Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q4 2022 and held it in 2 quarters.
Schechter Investment Advisors's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $1.45K in Q4 2022.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Schechter Investment Advisors's 13F filing for Q2 2023, filed 26 Jul 2023.